R
Ruth Link-Gelles
Researcher at Centers for Disease Control and Prevention
Publications - 87
Citations - 4545
Ruth Link-Gelles is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 47 publications receiving 2296 citations. Previous affiliations of Ruth Link-Gelles include United States Department of Health and Human Services & National Center for Immunization and Respiratory Diseases.
Papers
More filters
Journal ArticleDOI
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: Analysis of multisite, population-based surveillance
Matthew R. Moore,Ruth Link-Gelles,William Schaffner,Ruth Lynfield,Catherine Lexau,Nancy M. Bennett,Susan Petit,Shelley M. Zansky,Lee H. Harrison,Arthur Reingold,Lisa Miller,Karen Scherzinger,Ann Thomas,Monica M. Farley,Monica M. Farley,Elizabeth R. Zell,Thomas H. Taylor,Tracy Pondo,Loren Rodgers,Lesley McGee,Bernard Beall,James H. Jorgensen,Cynthia G. Whitney +22 more
TL;DR: PCV13 reduced IPD across all age groups when used routinely in children in the USA, providing reassurance that, similar to PCV7, PCVs with additional serotypes can also prevent transmission to unvaccinated populations.
Journal ArticleDOI
Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.
Daniel R. Feikin,Eunice W. Kagucia,Jennifer D. Loo,Ruth Link-Gelles,Milo A. Puhan,Thomas Cherian,Orin S. Levine,Cynthia G. Whitney,Katherine L. O'Brien,Matthew R. Moore +9 more
TL;DR: In a pooled analysis of data collected from invasive pneumococcal disease surveillance databases, Daniel Feikin and colleagues examine serotype replacement after the introduction of 7-valent pneumococCal conjugate vaccine (PCV7) into national immunization programs.
Journal ArticleDOI
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands,S. Rao,Brian E. Dixon,Patrick K. Mitchell,Malini B. DeSilva,Stephanie A. Irving,Ned Lewis,Karthik Natarajan,Edward Stenehjem,Shaun J. Grannis,Jungmi Han,Charlene McEvoy,Toan C. Ong,Allison L. Naleway,Sara E. Reese,Peter J. Embi,Kristin Dascomb,Nicola P. Klein,E. Griggs,D. Konatham,Anupam B. Kharbanda,Duck-Hye Yang,William F. Fadel,Nancy Grisel,Kristin Goddard,Palak Patel,I-Chia Liao,Rebecca Birch,Nimish Valvi,Sue Reynolds,Julie Arndorfer,Ousseny Zerbo,M. Dickerson,Kempapura Murthy,Jeremiah Williams,Catherine H Bozio,Lenee Blanton,Jennifer R. Verani,Stephanie J. Schrag,Alexandra F. Dalton,Mehiret Wondimu,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Michelle A. Barron,Manjusha Gaglani,Mark Thompson,Bruce Fireman +46 more
TL;DR: VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination, and VE was generally higher for protection against hospitalizations than against ED/UC visits.
Journal ArticleDOI
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark Thompson,Karthik Natarajan,Stephanie A. Irving,Elizabeth Rowley,E. Griggs,Manjusha Gaglani,Nicola P. Klein,Shaun J. Grannis,Malini B. DeSilva,Edward Stenehjem,Sara E. Reese,M. Dickerson,Allison L. Naleway,Jungmi Han,D. Konatham,Charlene McEvoy,S. Rao,Brian E. Dixon,Kristin Dascomb,Ned Lewis,M. Levy,Palak Patel,I-Chia Liao,Anupam B. Kharbanda,Michelle A. Barron,William F. Fadel,Nancy Grisel,Kristin Goddard,Duck-Hye Yang,Mehiret Wondimu,Kempapura Murthy,Nimish Valvi,Julie Arndorfer,Bruce Fireman,M. Dunne,Peter J. Embi,Eduardo Azziz-Baumgartner,Ousseny Zerbo,Catherine H Bozio,Sue Reynolds,Jill M. Ferdinands,Jeremiah Williams,Ruth Link-Gelles,Stephanie J. Schrag,Jennifer R. Verani,Sarah Ball,Toan C. Ong +46 more
TL;DR: The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine, and all unvaccinated persons should get vaccinated as soon as possible.
Journal ArticleDOI
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Srinivas Nanduri,Tamara Pilishvili,Gordana Derado,Minn M. Soe,Philip Dollard,Hsiu Wu,Qunna Li,Suparna Bagchi,Heather Dubendris,Ruth Link-Gelles,John A. Jernigan,Daniel S. Budnitz,Jeneita M. Bell,Andrea L. Benin,Nong Shang,Jonathan R. Edwards,Jennifer R. Verani,Stephanie J. Schrag +17 more
TL;DR: In this article, the authors evaluated the effectiveness of the two currently authorized mRNA COVID-19 vaccines against SARS-CoV-2 B.1.2 (Delta) and B.2.